Work

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

Year: 2022

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-022-01276-w

Authors: Nabil Adra, David J. Vaughn, Lawrence H. Einhorn, Nasser H. Hanna, Samuel A. Funt, Matt Rosales, Ahsan Arozullah, Darren R. Feldman

Institutions: Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Abramson Cancer Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Astellas Pharma (United States)

Language: English

Topic: Testicular diseases and treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Astellas Pharma US, Astellas Pharma, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W4283585171

FWCI: 6.543

Cites: 23

Cited by: 45

Related to: 10